Cormedix Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed March 12, 2024. This is an annual filing, not a standalone fourth-quarter report, and the supplied filing text does not provide separate Q4 results.
Business context
CorMedix is a biopharmaceutical company whose primary focus is commercializing DefenCath in the United States. The FDA approved DefenCath on November 15, 2023, for reducing catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter. The company described it as the first and only FDA-approved antimicrobial catheter lock solution in the U.S.; a Phase 3 study showed a reduction in infection risk of up to 71%. The company was preparing for a planned second-quarter 2024 launch.
Neutrolin sales in the EU and Middle East were discontinued in 2022, and the company said the EU wind-down was nearly complete. Taurolidine research for pediatric neuroblastoma remained preclinical.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 | Change / context |
|---|---|---|---|
| Revenue | $0 | $65,408 | 2023 sales ceased following the Neutrolin wind-down. |
| Gross profit | $0 | $61,674 | No 2023 revenue; gross margin is not meaningful. |
| Research and development | $13.16 million | $10.68 million | Up 23%. |
| Selling, general and administrative | $35.80 million | $20.01 million | Up 79%, mainly from DefenCath pre-launch activity and additional personnel. |
| Operating loss | $48.96 million | $30.62 million | Loss widened 60%. |
| Net loss | $46.34 million | $29.70 million | Loss widened 56%; basic and diluted loss per share was $0.91 versus $0.74. |
| Net cash used in operations | $38.41 million | $24.36 million | Higher operating costs, including launch preparation. |
| Cash and cash equivalents plus short-term investments | $76.03 million | $58.79 million | Excludes restricted cash. |
FY 2023 interest income was $2.68 million, compared with $0.33 million in 2022. The 2022 results included a $586,000 tax benefit from selling New Jersey net operating losses; no such tax benefit was recorded in 2023. The company reported an accumulated deficit of $321.70 million.
Cash provided by financing activities was $55.92 million, primarily from a public offering and at-the-market stock sales. Net proceeds were $42.88 million from the public offering and $12.95 million from the ATM program. Investing activities used $17.06 million, mainly reflecting purchases of short-term investments. Common shares issued and outstanding increased from 42.82 million at year-end 2022 to 54.94 million at year-end 2023.
At year-end, current assets were $79.45 million and current liabilities were $11.40 million. Total liabilities were $11.92 million, including $668,000 of operating lease liabilities; the balance sheet reports no conventional borrowings. Outstanding preferred stock had an aggregate liquidation preference of approximately $21.29 million and includes debt and other covenants. The company said its cash and short-term investments were expected to fund operations for at least 12 months from the filing’s issuance and the launch through anticipated profitability, based on a second-quarter 2024 launch and other assumptions. It also disclosed $104.4 million remaining under its shelf registration statement.
Approximately $6.41 million of pre-approval manufacturing inventory costs had already been expensed as R&D; inventory recorded after approval was $2.11 million at December 31, 2023.
Material changes and outlook
- FDA approval: DefenCath moved from development to approved product in November 2023, but had generated no product revenue by year-end.
- Commercial reimbursement: CMS finalized a FY 2024 inpatient NTAP of up to $17,111 per hospital stay, calculated using an anticipated $1,170 WAC per 3 mL vial. CorMedix later set actual WAC at $249.99 per vial. The company expected CMS to revisit the NTAP in October 2024; CMS had said it would not make an off-cycle adjustment.
- Outpatient reimbursement: CMS classified DefenCath as a renal dialysis service under ESRD PPS in January 2024. The company had applied for a HCPCS J-code and TDAPA. CMS was working toward a July 1, 2024 implementation date subject to favorable review; approval and timing were not guaranteed. TDAPA and post-TDAPA payments could collectively apply for five years if approved.
- Supply chain: The approved product depended on one FDA-approved source for each key active ingredient and one approved finished-dose manufacturing site. CorMedix planned to qualify alternate ingredient sources and submit a supplement for Siegfried Hameln as an alternate site; it planned to end its potential-site relationship with Alcami.
- Post-approval obligation: FDA deferred, but required, a pediatric study under PREA. Any additional six months of pediatric exclusivity is uncertain. The company also said it would discuss possible pathways for expanded indications in 2024; oncology and total parenteral nutrition were potential areas, not approved uses.
Risks, contingencies and other notable items
- The company has a history of losses, expects further losses and may need additional capital. Future equity financing could dilute shareholders; debt or collaborations could impose restrictions or require relinquishing rights.
- Commercial success depends on reimbursement, provider adoption and pricing. Two dialysis providers account for more than 70% of outpatient dialysis treatments, creating customer concentration risk.
- Manufacturing is outsourced, with single-source exposure for key ingredients and the approved finished-dose site. Delays, quality issues or failure to qualify alternatives could constrain supply.
- A securities class action concerning past DefenCath regulatory disclosures remained pending on a motion to dismiss. Related derivative litigation was stayed pending resolution of the class action. Management said it intended to contest the claims; it did not consider current proceedings likely to have a material adverse effect.
- The company reported no material cybersecurity incidents during the period. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2023; the auditor did not provide an opinion on internal control.
- The independent auditor issued an unqualified opinion on the financial statements and reported no critical audit matters.
Important facts for investors to verify
- Whether DefenCath launched as planned and the resulting sales, adoption, realized pricing and gross margin.
- CMS decisions and effective dates for the HCPCS code and TDAPA, and the final inpatient NTAP amount after the actual WAC was considered.
- Whether major dialysis providers adopted DefenCath and on what commercial terms.
- Progress in qualifying alternate ingredient suppliers and manufacturing sites, including FDA review of the planned site supplement.
- Actual cash burn and runway versus management’s launch, penetration, pricing and cost assumptions; any subsequent financing or dilution.
- Developments in the securities and derivative litigation, the required pediatric study, and any progress toward expanded indications.